This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
ViaCyte Identifier:
First received: September 9, 2014
Last updated: May 18, 2017
Last verified: May 2017
The purpose of this trial is to test if VC-01™ combination product can be implanted subcutaneously in subjects with Type 1 Diabetes and maintained safely for two years. It will also test if VC-01 is an effective treatment for subjects with Type 1 Diabetes.

Condition Intervention Phase
Type 1 Diabetes Mellitus Device: VC-01™ Combination Product Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Prospective, Multicenter, Open-Label, First-in-Human Phase 1/2 Study With Two Cohorts to Evaluate the Safety, Tolerability, and Efficacy of Various Doses of VC-01™ Combination Product in Subjects With Type 1 Diabetes Mellitus

Resource links provided by NLM:

Further study details as provided by ViaCyte:

Primary Outcome Measures:
  • Incidence of all adverse events reported during the study. [ Time Frame: Thru the Month 24 Visit ]
  • Change in C-peptide [ Time Frame: Baseline to the Month 6 Visit ]

Estimated Enrollment: 65
Actual Study Start Date: September 2014
Estimated Study Completion Date: January 2021
Estimated Primary Completion Date: January 2021 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1
2 VC-01 implants
Device: VC-01™ Combination Product
Biologic and Device
Experimental: Cohort 2
4 or 6 VC-01 implants
Device: VC-01™ Combination Product
Biologic and Device


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women (non-pregnant and non-childbearing potential)
  • Diagnosis of type 1 diabetes mellitus for at least 3 years
  • Stable diabetic treatment
  • Willingness to use a continuous glucose meter
  • Acceptable candidate for implantation

Exclusion Criteria:

  • Advanced complications associated with diabetes
  • Immunosuppressive therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02239354

United States, California
University of California at San Diego
San Diego, California, United States
Additional Sites to be Added in Other Cities and States
TBD, California, United States
Canada, Alberta
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2B7
Sponsors and Collaborators
  More Information

Responsible Party: ViaCyte Identifier: NCT02239354     History of Changes
Other Study ID Numbers: VC01-101
Study First Received: September 9, 2014
Last Updated: May 18, 2017

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases processed this record on September 21, 2017